Inmanol-Martínez-Salas

Imanol Martinez Salas

Médico Especialista
Specialty:
Medical oncology
Serving specialties:
  • Oncología Médica
E-mail: Imanol.martinez@quironsalud.es
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
Consultation: 5 (1er piso)
Opening times: De 7:30 a.m. a 3:00 p.m. de lunes a viernes
General Information
Experience
  • Resident physician in the Department of Medical Oncology at FJD Hospital. 20/05/2015 - 20/05/2020.
  • Specialist physician in the Department of Medical Oncology at La Luz Hospital. 01/06/2020 - 11/11/2020.
  • Specialist physician in the Medical Oncology Department at FJD Hospital. 11/12/2020 - Present.
Degree
  • Degree in Medicine and Surgery (University of Navarra). 2008 a 2014
  • Master's Degree in Integration and Resolution of Clinical Problems in Medicine (University of Alcalá). 2015
  • Master's Degree in Continuing Education in Genitourinary Tumors (Complutense University of Madrid). 2024.
Insurance companies
  • ADESLAS
  • AEGÓN
  • AGRUPACIÓN ANFI
  • ASISA
  • AXA SEGUROS GENERALES
  • CATALANA OCCIDENTE
  • CÁSER
  • CIGNA
  • DIVINA PASTORA
  • DKV
  • GENERALI
  • HERMANDAD NACIONAL DE ARQUITECTOS (HNA)
  • MAPFRE
  • MUSA
  • UNIÓN MADRILEÑA
  • PRIVADOS
Research and teaching

Research:

- Principal investigator of the clinical trial MEVPRO 3: A phase 3, randomized, double-blind, placebo-controlled study of mevrometostat (pf-06821497) with enzalutamide in metastatic castration-sensitive prostate cancer.
- Principal investigator of the clinical trial MEVPRO 2. A phase 3, randomized, double blind, placebo controlled study of pf-06821497 (mevrometostat) with enzalutamide in metastatic castration resistant prostate cancer.
- Principal investigator of the clinical trial MEVPRO 1: A phase 3, randomized, open-label study of pf-06821497 (mevrometostat) in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously treated with abiraterone acetate.
- Principal investigator of the clinical trial DURAVELO-2: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer.
- Principal investigator of the clinical trial SSANTROP: A Phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive NMIBC patients.
- Principal investigator of the clinical trial PROSFIT: Smart wearables to evaluate the impact of lifestyle changes in patients with metastatic hormone sensitive prostate cancer (mHSPC).
- Principal investigator of the clinical trial STELLAR-002: Study of XL092 in combination with immuno-oncology agents in subjects with solid tumors. Phase 1b clinical trial.
- Principal investigator of the clinical trial ECLIPSE: 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. Phase 3 clinial trial.
Principal investigator of the clinical trial TAVANTA: a novel abiraterone acetato oral suspension for patients with metastic prostate cancer. Phase 3 clinical trial.

Teaching:

Teaching collaborator in the subject of Medical Oncology at the Autonomous University of Madrid and Alfonso X El Sabio University.

Publications

- Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical and Translational Oncology, 06/10/2024.
- Nerea Muñoz-Unceta; Jon Zugazagoitia; Imanol Martínez-Salas. High Risk Of Thrombosis In Patients With Advanced Lung Cancer Harboring Rearrangements In Ros1. European Journal of Cancer. 141, pp. 193 - 198. Elsevier, 11/10/2020.
- Cristina Caramés; Ion Cristobal; Pablo Minguez; Víctor Moreno; Ana Leon; Héctor Callata Carhuapoma; José Ignacio Martín Valadés; Manuel Dómine; Roberto Hernández; Manuel Pedregal; Imanol Martínez Salas. MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer.Annals of Oncology. 27 - 6, pp. 179. 01/10/2016.
Manuel Dómine Gómez; Imanol Martínez Salas; Manuel Pedregal; Víctor Zénzola. Inmunoterapia: nuevo paradigma en el tratamiento del cáncer de pulmón microcítico.Revisiones en cáncer. 33 - 1, pp. 149 - 153. XXI Simposio de revisiones en cáncer, 01/02/2019.

Communications and Presentations

Multiple presentations at national conferences.